Ocular Therapeutix, Inc (OCUL) stock
Close on Nov 11, 2026Market cap $1.46BP/E –Yield –
Ocular Therapeutix, Inc saw revenue fall 9.7% to $50.38M over the twelve months to Sep 30, 2026. Free cash flow was -$267.04M. At the latest close the market valued the company at $1.46B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.46B
- P/E ratio
- –
- Price to sales
- 29.03
- Price to book
- 3.32
- Dividend yield
- –
- Free cash flow yield
- -18.26%
Fundamentals
- Revenue
- $50.38M
- Net income
- -$326.81M
- EPS, diluted
- -$1.46
- Free cash flow
- -$267.04M
- Book value per share
- $1.96
- Diluted shares
- 226M
Trading
- Next earnings
- Feb 4, 2027 (estimated, before the open)
- Previous close
- $6.61
- Open
- $6.63
- Day's range
- $6.48 – $6.82
- Volume
- 2,989,841
- Average volume (20 days)
- 2,830,960
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 1.26
- 52-week range
- $6.00 – $16.44
- RSI (14 days)
- 42.7
- Volatility (1 year)
- 75.9%
- Relative volume
- 1.06×
- WACC
- 11.2%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | OCUL | S&P 500 | Difference | OCUL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -11.7% | -2.4% | −9.3 pts | ||
| 3 months | -31.8% | -1.2% | −30.6 pts | ||
| Year to date | -45.1% | +12.3% | −57.4 pts | ||
| 1 year | -40.6% | +12.4% | −53.1 pts | ||
| 3 years | +216.4% | +78.8% | +137.6 pts | +46.8% | +21.4% |
| 5 years | -11.3% | +75.2% | −86.5 pts | -2.4% | +11.9% |
| 10 years | -3.1% | +311.1% | −314.2 pts | -0.3% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Ocular Therapeutix filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- News
About Ocular Therapeutix
Pharmaceutical Preparations
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for eye diseases and conditions using its proprietary bioresorbable hydrogel-based formulation technology, ELUTYX. Its primary commercial product is DEXTENZA, which is indicated for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. In addition, the company develops investigational therapies including AXPAXLI, a product candidate in clinical evaluation for wet age-related macular degeneration and non-proliferative diabetic retinopathy, as well as OTX-TIC for open-angle glaucoma and ocular hypertension.
Company profile, executives and historyOcular Therapeutix stock: common questions
What is Ocular Therapeutix's stock price?
OCUL closed at $6.66 on Nov 11, 2026, up 0.76% on the day. Over the past 52 weeks it traded between $6.00 and $16.44.
What is Ocular Therapeutix's market cap?
Ocular Therapeutix was worth $1.46B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is OCUL's P/E ratio?
Ocular Therapeutix lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.46), so it has no meaningful P/E ratio.
How much revenue does Ocular Therapeutix make?
Ocular Therapeutix reported revenue of $50.38M for the twelve months to Sep 30, 2026, down 9.7% from a year earlier.
Does Ocular Therapeutix pay a dividend?
No. Ocular Therapeutix has not paid a cash dividend over the last twelve months.
When does Ocular Therapeutix report earnings next?
Ocular Therapeutix is expected to report Q4 FY2026 results on Feb 4, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has OCUL stock performed over the past year?
Including dividends, OCUL returned -40.6% over the past year, against +12.4% for the S&P 500.
How many OCUL shares are sold short?
29M shares were sold short at the latest FINRA report, 13.59% of the float, or 10.1 days of average trading volume.
Who are Ocular Therapeutix's competitors?
Companies most similar to Ocular Therapeutix by business, industry and size include SPRO, TNXP, BFRI, XLO, AYTU.
See a number that looks wrong?